Differences

This shows you the differences between two versions of the page.

--- projects:workgroups:kb-wg [2015/06/23 09:48]
lee
+++ projects:workgroups:kb-wg [2017/06/02 21:18]
rkboyce
@@ Line 1: / Line 1: @@
-====== Knowledgebase (LAERTES) Workgroup ======
+====== Pharmacovigilance evidence investigation Workgroup (used to be Knowledge Base / LAERTES)  ======
 <WRAP box justify round>
-**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first release of LAERTES is schedule for April 2015
+**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first staging release of LAERTES occurred last year and is reported in https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3.
 **Project Lead:**  [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]]
-**Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/1045-2/|Patrick Ryan, PhD]]
+**Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]]
 **Members:**
-See [[kb-wg#internal|Members List]]
+See [[kb-wg#internal|Members List]] but note that active membership is completely voluntary and open.
 **Start Date:** 6/10/2014
@@ Line 17: / Line 17: @@
 **Repository:**  [[https://github.com/OHDSI/KnowledgeBase]]
-**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|Knowledge Base WG Minutes]]
+**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|WG Minutes]]
+**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172| WG Agendas]]
+**Publications:**
+Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. Available at: https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176.
+E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005.
+Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0
-**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172|Knowledge Base WG Agendas]]
 </WRAP>
@@ Line 25: / Line 36: @@
 ==== Meetings (Telecon Info) ====
-    Schedule: Every other Wednesday at 12 Eastern starting from January 14th 2015
+    Schedule:
-    Please join my meeting.
-    https://global.gotomeeting.com/join/530277469
+    - All team call once per month on the 4th Wednesday of each month at 9-10 Eastern. NOTE: no call in June. Back on schedule starting 7/26/17
+    - Touch point call on the 2nd Wednesday of each month 9-10 Eastern starting on 7/12/17
-    You can call in for audio:
-    Dial +1 (646) 749-3122
-    Access Code: 530-277-469
+ Please join my meeting from your computer, tablet or smartphone.
+ https://global.gotomeeting.com/join/530277469
-=== Discussions ===
+You can also dial in using your phone.
+ United States: +1 (224) 501-3217
-[[http://forums.ohdsi.org/t/laertes-api/128|Laertes API]]
+ Access Code: 530-277-469
-[[http://forums.ohdsi.org/t/laertes-update-of-the-pharmacovigilance-signals/173/1|update of the pharmacovigilance signals]]
+ More phone numbers
+ Canada: +1 (647) 497-9350
+ France: +33 170 950 594
+ Netherlands: +31 207 941 377
+ Sweden: +46 853 527 836
+ Switzerland: +41 225 4599 78
+ United Kingdom: +44 330 221 0088
-[[http://forums.ohdsi.org/t/laertes-pre-load-queries-hoi-from-x-to-snomed-rxnorm-bd-to-cd/180|LAERTES: pre-load queries - hoi from X to snomed, rxnorm BD to CD]]
-[[http://forums.ohdsi.org/t/laertes-getting-the-pivot-correct-rolling-up-from-clinical-drug-to-ingredient/181|LAERTES: getting the pivot correct - ‘rolling up’ from clinical drug to ingredient]]
+=== Discussions ===
+Search for "LAERTES" on [[http://forums.ohdsi.org/]]
 === GitHub Issues ===
-{{ghissues OHDSI/KnowledgeBase state:open}}
+[[https://github.com/OHDSI/KnowledgeBase/issues]]
+=== Members List (add or delete your name if you see an omission or error) ===
-=== Members List ===
+Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, rdb20@pitt.edu
-- Abraham G. Hartzema, PhD, University of Florida, Gainesville, FL
+Erica A. Voss, Janssen Research & Development, LLC, Titusville, NJ, EVoss3@its.jnj.com
-- Christian Reich, MD, PhD, AstraZeneca, Waltham MA
+Vojtech Huser, National Institutes of Health, Bethesda, MD, vojtech.huser@nih.gov
-- Christophe Lambert, PhD, University of New Mexico, Albuquerque, NM
+Lee Evans, LTS Computing LLC, West Chester, PA, levans@ltscomputingllc.com
-- Erica A. Voss, MPH, Janssen Research and Development, Titusville, PA
+Christian Reich, QuintilesIMS, Burlington MA, reich@ohdsi.org
-- Gianluca Trifirò, PhD, University of Messina, Messina, Italy & Erasmus University Medical Center, Rotterdam, Netherlands
+Jon D. Duke, Georgia Tech Research Institute, Atlanta, GA, Jon.Duke@gatech.edu
-- J. Marc Overhage, MD, PhD, Siemens Healthcare, Malvern, PA
+Nicholas P. Tatonetti, Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University, New York, NY, nick.tatonetti@columbia.edu
-- Jon Duke, MD, Regenstrief Institute, Indianapolis IN
+Tal Lorberbaum, Columbia University, New York, NY, tal.lorberbaum@columbia.edu
-- Johan Ellenius, PhD, Uppsala Monitoring Centre, Uppsala, Sweden
+Michel Dumontier, Stanford University, Stanford, CA, michel.dumontier@gmail.com
-- Lee Evans, LTS Computing LLC, West Chester, PA
+Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center,  New York, NY, manfred.hauben@pfizer.com
-- Majid Rastegar-Mojarad, MS, Mayo Clinic, Rochester, MN
+Magnus Wallberg, Uppsala Monitoring Centre, Uppsala, Sweden, Magnus.Wallberg@who-umc.org
-- Mark Khayter, BS, Ephir, Boston, MA
+Lili Peng, AstraZeneca R&D, Boston , MA, Lili.Peng@astrazeneca.com
-- Martijn J. Schuemie, PhD, Janssen Research and Development, Titusville, PA
+Sara Dempster, AstraZeneca R&D, Boston , MA, sara.dempster@astrazeneca.com
-- Michel Dumontier, PhD, Stanford University, Stanford, CA
+Yongqun He, University of Michigan Medical School, Ann Arbor, Michigan, yongqunh@med.umich.edu
-- Nicholas P. Tatonetti, PhD, Columbia University, New York, NY
+Anthony G. Sena, Janssen Research & Development, LLC, Titusville, NJ, asena5@its.jnj.com
-- Niklas Noren, PhD, Uppsala Monitoring Centre, Uppsala, Sweden
+Vassilis Koutkias, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, vkoutkias@certh.gr
-- Rave Harpaz, PhD, Stanford University, Palo Alto, CA
+Pantelis Natsiavas, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, pnatsiavas@certh.gr
-- Vojtech Huser, MD PhD, National Institutes of Health, Bethesda, MD
+Patrick B. Ryan, Janssen Research & Development, LLC, Titusville, NJ, ryan@ohdsi.org

Observational Health Data Sciences and Informatics

User Tools

Site Tools

Differences

Page Tools